Printer Friendly

AMERICAN BIOGENETIC SCIENCES FIBRIN ANTIBODY PATENT ALLOWED

 AMERICAN BIOGENETIC SCIENCES FIBRIN ANTIBODY PATENT ALLOWED
 NOTRE DAME, Ind., Dec. 5 /PRNewswire/ -- American Biogenetic Sciences, Inc. ("ABS") (NASDAQ: MABXA), announced today that it has received notice from the United States Patent and Trademark Office allowing its monoclonal antibody MH-1 patent application.
 ABS President Henry L. Nordhoff estimates the potential worldwide annual market for blood clot imaging agents at $1 billion. ABS is also developing MH-1 as a vehicle to deliver clot dissolving drugs to the site of a clot, the market for which is estimated to be twice as large as the imaging agent market.
 Pre-clinical animal studies have demonstrated that MH-1, linked to technetium using ABS's proprietary direct labeling technology, can determine the size and location of blood clots in the heart and lungs in just 30 minutes and two hours, respectively, after injection. Blood clots leading to heart attack and stroke are the leading cause of death in the developed world. When a prompt diagnosis is made, these events can often be successfully treated. Human studies will commence in early 1992 after which FDA marketing clearance will be sought.
 American Biogenetic Sciences, Inc., is a biopharmaceutical company that conducts research and development at the University of Notre Dame in Notre Dame, Ind., and Trinity College, Dublin, Ireland. Its primary corporate objective is to commercialize monoclonal antibody-based products which diagnose, prevent and treat cardiovascular disease. The monoclonal antibodies are generated from the company's unique antigen- free mouse colony. ABS is also developing recombinant vaccine for major diseases currently lacking effective vaccine protection.
 -0- 12/5/91
 /CONTACT: Henry L. Nordhoff, president of ABS, 203-221-2752; or Anthony J. Russo or Bonnie Sterling of Noonan/Russo Communications, 212-979-9180, for ABS/
 (MABXA) CO: American Biogenetic Sciences, Inc. ST: Indiana IN: MTC SU:


GK-OS -- NY009 -- 9492 12/05/91 08:53 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 5, 1991
Words:300
Previous Article:CHARMING SHOPPES REPORTS NOVEMBER SALES
Next Article:GANTOS, INC. ANNOUNCES NOVEMBER 1991 SALES
Topics:


Related Articles
AMERICAN BIOGENETIC SCIENCES SIGNS LICENSE AGREEMENT WITH YAMANOUCHI PHARMACEUTICAL
ABS PREVIEWS CARDIOVASCULAR PRODUCTS
DEACONESS HOSPITAL AND HARVARD MEDICAL SCHOOL REPORT SIGNIFICANT PROGRESS IN CLINICAL EVALUATION;
AMERICAN BIOGENETIC SCIENCES, INC. ANNOUNCES ITS COMPLETION OF PHASE I, INITIATION OF PHASE I II CLINICAL TRIAL OF MH1 FOR IMAGING BLOOD CLOTS
AMERICAN BIOGENETIC SCIENCES, INC. ANNOUNCES PRESENTATION OF THREE ABSTRACTS ON ITS SOLFIB ASSAY AT CONGRESS OF THE INTERNATIONAL SOCIETY ON...
AMERICAN BIOGENETIC SCIENCES ISSUED U.S. PATENT NO. 5,453,359 FOR THROMBUS PRECURSOR PROTEIN (TpP) (SOLUBLE FIBRIN POLYMER)
American Biogenetic Sciences, Inc. Receives FDA Clearance for its Patented Thrombus Precursor Protein (TpP) Diagnostic Test
American Biogenetic Sciences, Inc. Obtains Key US Patent for Novel Compounds With the Potential to Treat Neurodegenerative Disorders
American Biogenetic Sciences Announces U.S. Patent and Presentation of Data on New Epilepsy Compound

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters